NCT05238402

Brief Summary

In the retrospective case series, consecutive COVID-19 patients admitted from June 1 to December 31, 2020, were analyzed. A 1:1 matched cohort was created by propensity score-matched analysis. Demographic data, laboratory findings, comorbidities, treatments, and in-hospital outcomes were collected and compared between COVID-19 patients with and without statin use.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
707

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2020

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2021

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

February 9, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 14, 2022

Completed
Last Updated

February 14, 2022

Status Verified

February 1, 2022

Enrollment Period

7 months

First QC Date

February 9, 2022

Last Update Submit

February 10, 2022

Conditions

COVID-19

Keywords

COVID-19CoronavirusHigh cardiovascular riskPandemicStatin Therapy

Outcome Measures

Primary Outcomes (1)

  • Mortality

    In-hospital mortality

    up to 1 month

Study Arms (2)

on statins

patients who received a statin

Drug: Statin

not on statins

patients who not received a statin

Drug: Statin

Interventions

StatinDRUG

Statin on COVID 19 patienst

not on statinson statins

Eligibility Criteria

Age40 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

We conducted a retrospective single-center review of all patients admitted to Antalya Training and Research Center in Antalya Turkey, tested positive for SARS-CoV-2 reverse transcriptase-polymerase chain reaction testing of nasopharyngeal or oropharyngeal specimens from January 1, 2020, to December 31, 2020

You may qualify if:

  • COVID 19 diagnosis
  • Very high cardiovascular risk

You may not qualify if:

  • \< 40 years old

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Deniz Demirci

Antalya, Turkey (Türkiye)

Location

MeSH Terms

Conditions

COVID-19Coronavirus Infections

Interventions

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Anticholesteremic AgentsHypolipidemic AgentsAntimetabolitesMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesEnzyme InhibitorsLipid Regulating AgentsTherapeutic Uses

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
6 Months
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 9, 2022

First Posted

February 14, 2022

Study Start

June 1, 2020

Primary Completion

December 31, 2020

Study Completion

March 31, 2021

Last Updated

February 14, 2022

Record last verified: 2022-02

Locations

TU(1)